Description

According to StrategyHelix, the global emerging therapeutics for hematological malignancies market is expected to increase by US$ 12.0 billion during 2022-2028, expanding at a CAGR of 13.4% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for emerging therapeutics for hematological malignancies. The global emerging therapeutics for hematological malignancies market is segmented on the basis of type, indication, and region. Based on type, the global emerging therapeutics for hematological malignancies market is categorized into CAR T-cell therapies, monoclonal antibodies. The monoclonal antibodies segment captured the largest share of the market in 2021. On the basis of indication, the global emerging therapeutics for hematological malignancies market has been segmented into leukemia, lymphoma, multiple myeloma. Geographically, the global emerging therapeutics for hematological malignancies market is segmented into Asia Pacific, Europe, North America, Rest of the World (RoW).

The CAR T-cell therapies market is further segmented into tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), and others. Furthermore, the monoclonal antibodies market has been categorized into blinatumomab (Blincyto), brentuximab vedotin (Adcetris), daratumumab (Darzalex), inotuzumab ozogamicin (Besponsa), obinutuzumab (Gazyva), sintilimab (Tyvyt), and others.

The global emerging therapeutics for hematological malignancies market is highly competitive. The prominent players operating in the global emerging therapeutics for hematological malignancies market include AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company (BMS), F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics Inc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited. Competitive landscape gives a description of the competitive nature of the global emerging therapeutics for hematological malignancies market and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the emerging therapeutics for hematological malignancies market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Type: CAR T-cell therapies, monoclonal antibodies
Indication: leukemia, lymphoma, multiple myeloma
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028
Company mentioned: AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company (BMS), F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics Inc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited

Key Benefits for Stakeholders

– Get a comprehensive picture of the global emerging therapeutics for hematological malignancies market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Emerging therapeutics for hematological malignancies market overview
Part 3. Market breakdown by type
– CAR T-cell therapies
– Monoclonal antibodies
Part 4. Market breakdown by indication
– Leukemia
– Lymphoma
– Multiple myeloma
Part 5. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 6. Key companies
– AbbVie Inc.
– Amgen Inc.
– Bristol-Myers Squibb Company (BMS)
– F. Hoffmann-La Roche AG
– Gilead Sciences, Inc.
– GlaxoSmithKline plc
– Immune-Onc Therapeutics, Inc.
– Johnson & Johnson
– Merck & Co., Inc.
– Novartis AG
– Pfizer Inc.
– Sanofi S.A.
– Takeda Pharmaceutical Company Limited
About StrategyHelix
Disclaimer